KR20090008459A - Ｒａｇｅ 융합 단백질, 제제 및 이의 사용 방법 - Google Patents

Ｒａｇｅ 융합 단백질, 제제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20090008459A
KR20090008459A KR1020087029731A KR20087029731A KR20090008459A KR 20090008459 A KR20090008459 A KR 20090008459A KR 1020087029731 A KR1020087029731 A KR 1020087029731A KR 20087029731 A KR20087029731 A KR 20087029731A KR 20090008459 A KR20090008459 A KR 20090008459A
Authority
KR
South Korea
Prior art keywords
rage
fusion protein
seq
amino acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087029731A
Other languages
English (en)
Korean (ko)
Inventor
애드넌 엠.엠. 음잘리
로버트 로들린
예 에드워드 티안
제프리 씨. 웹스터
에릭 제이. 벤자민
Original Assignee
트랜스테크 파르마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트랜스테크 파르마, 인크. filed Critical 트랜스테크 파르마, 인크.
Publication of KR20090008459A publication Critical patent/KR20090008459A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
KR1020087029731A 2006-05-05 2007-04-25 Ｒａｇｅ 융합 단백질, 제제 및 이의 사용 방법 Withdrawn KR20090008459A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79845506P 2006-05-05 2006-05-05
US60/798,455 2006-05-05

Publications (1)

Publication Number Publication Date
KR20090008459A true KR20090008459A (ko) 2009-01-21

Family

ID=38521887

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087029731A Withdrawn KR20090008459A (ko) 2006-05-05 2007-04-25 Ｒａｇｅ 융합 단백질, 제제 및 이의 사용 방법

Country Status (21)

Country Link
US (2) US7981424B2 (https=)
EP (2) EP2021474A2 (https=)
JP (1) JP5558810B2 (https=)
KR (1) KR20090008459A (https=)
CN (1) CN101548012A (https=)
AR (1) AR060862A1 (https=)
AU (1) AU2007248784B2 (https=)
BR (1) BRPI0711193A2 (https=)
CA (1) CA2651348A1 (https=)
DO (1) DOP2007000089A (https=)
EA (1) EA017291B1 (https=)
IL (1) IL194482A0 (https=)
MX (1) MX2008013863A (https=)
NL (1) NL2000626A1 (https=)
NZ (1) NZ571692A (https=)
PE (1) PE20080397A1 (https=)
SG (1) SG171670A1 (https=)
TW (1) TW200801036A (https=)
UY (1) UY30324A1 (https=)
WO (1) WO2007130302A2 (https=)
ZA (1) ZA200809394B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20105110B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
SG161242A1 (en) * 2004-08-03 2010-05-27 Transtech Pharma Inc Rage fusion proteins and methods of use
JP5314428B2 (ja) * 2005-12-23 2013-10-16 ジーコデール システムズ アクチボラゲット 測位用パターン
EP1989227A2 (en) * 2006-02-09 2008-11-12 Transtech Pharma, Inc. Rage fusion proteins and methods of use
SG171670A1 (en) 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100216977A1 (en) * 2007-02-15 2010-08-26 Kyushu University, National University Corporation Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
JP5225109B2 (ja) * 2007-02-15 2013-07-03 国立大学法人 熊本大学 ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤
WO2008099917A1 (ja) * 2007-02-15 2008-08-21 Fukuoka University 抗hmgb-1抗体を含む臓器移植拒絶抑制剤
KR101595634B1 (ko) 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
AU2010240569A1 (en) * 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
WO2013074820A1 (en) 2011-11-16 2013-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immunogenic tumor associated stromal cell antigen peptides and methods of their use
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
PL2925338T3 (pl) * 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
EP3077823B1 (en) 2013-12-05 2019-09-04 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
JP6617110B2 (ja) * 2014-10-01 2019-12-04 国立研究開発法人農業・食品産業技術総合研究機構 遺伝子組換えカイコにより生産したビオチン化酸化ｌｄｌ受容体・終末糖化産物受容体
EP3822291A1 (en) 2015-06-10 2021-05-19 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
WO2017106196A1 (en) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN112699601B (zh) * 2020-12-28 2022-05-31 电子科技大学 一种传感器网络数据的空时重构方法
US20230246158A1 (en) * 2022-02-02 2023-08-03 Enevate Corporation Cycle life in si/li batteries using high temperature deep discharge cycling

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
DE69629176T2 (de) 1995-01-18 2004-06-03 Alteon Inc. Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
FI119756B (fi) 1995-01-18 2009-03-13 Alteon Inc Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
CA2217572A1 (en) 1995-04-05 1996-10-10 The Picower Institute For Medical Research Agents for binding to advanced glycosylation endproducts, and methods of their use
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US7081241B1 (en) 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
JP2001514661A (ja) 1997-03-11 2001-09-11 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の処置における使用のための薬剤の同定
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
WO2000018970A1 (fr) 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Procede de commande de liberation de granules
SK4272001A3 (en) * 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
AU765719B2 (en) 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6605642B2 (en) 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6787566B2 (en) 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
CA2382095A1 (en) 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof
EP1219639A4 (en) 1999-09-08 2009-03-25 Toray Industries CIPO - Patent
US20050170382A1 (en) 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
CA2356207C (en) 1999-10-21 2012-10-09 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
JP2003516150A (ja) 1999-12-08 2003-05-13 ジェンセット 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ
US6716635B2 (en) 2000-04-14 2004-04-06 University Of Kentucky Research Foundation Method for identifying regulators of protein-advanced glycation end product (protein-AGE) formation
AU2001255436A1 (en) 2000-04-17 2001-10-30 Transtech Pharma Protein expression system arrays and use in biological screening
US6563015B1 (en) 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
CA2424246A1 (en) 2000-10-02 2002-04-11 Shianlen Cahoon Methods and compositions for the treatment of inflammatory diseases
AU2002213192A1 (en) 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
PL366250A1 (en) 2000-12-29 2005-01-24 Reddy Us Therapeutics, Inc. Detection of compounds that modulate inflammatory responses
CN100522242C (zh) 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
JP3837494B2 (ja) 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1575513A4 (en) 2002-08-16 2007-04-04 Wyeth Corp COMPOSITIONS AND METHODS FOR TREATING RAGE-ASSOCIATED DISEASES
US8067371B2 (en) 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
ZA200601810B (en) 2003-09-05 2008-05-28 Univ Columbia Rage-related methods and compositions for treating glomerular injury
US20070167360A1 (en) 2003-10-31 2007-07-19 Yan Shi D Methods for treating multiple sclerosis
US20060012414A1 (en) * 2004-07-15 2006-01-19 Texas Instruments Incorporated Circuit and method for generating a polyphase clock signal and system incorporating the same
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
EP1771565B1 (en) 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
SG161242A1 (en) 2004-08-03 2010-05-27 Transtech Pharma Inc Rage fusion proteins and methods of use
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
WO2006036922A2 (en) 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
US20080207499A1 (en) 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
EP1989227A2 (en) 2006-02-09 2008-11-12 Transtech Pharma, Inc. Rage fusion proteins and methods of use
SG171670A1 (en) 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins

Also Published As

Publication number Publication date
US20110282035A1 (en) 2011-11-17
EP2380983A3 (en) 2012-12-05
AU2007248784B2 (en) 2013-11-21
IL194482A0 (en) 2011-08-01
EA017291B1 (ru) 2012-11-30
NZ571692A (en) 2012-01-12
UY30324A1 (es) 2008-01-02
CA2651348A1 (en) 2007-11-15
MX2008013863A (es) 2008-11-14
JP2009536201A (ja) 2009-10-08
US7981424B2 (en) 2011-07-19
BRPI0711193A2 (pt) 2013-06-18
EP2380983A2 (en) 2011-10-26
US8344120B2 (en) 2013-01-01
CN101548012A (zh) 2009-09-30
WO2007130302A3 (en) 2008-04-03
WO2007130302A2 (en) 2007-11-15
EA200870502A1 (ru) 2009-06-30
ZA200809394B (en) 2009-07-29
SG171670A1 (en) 2011-06-29
US20080045455A1 (en) 2008-02-21
JP5558810B2 (ja) 2014-07-23
PE20080397A1 (es) 2008-04-28
AR060862A1 (es) 2008-07-16
DOP2007000089A (es) 2007-11-15
AU2007248784A1 (en) 2007-11-15
EP2021474A2 (en) 2009-02-11
TW200801036A (en) 2008-01-01
NL2000626A1 (nl) 2007-11-06

Similar Documents

Publication Publication Date Title
KR20090008459A (ko) Ｒａｇｅ 융합 단백질, 제제 및 이의 사용 방법
NL2000476C2 (nl) Rage-fusie-eiwitten en werkwijzen voor het gebruik ervan.
KR101323411B1 (ko) Ｒａｇｅ 융합 단백질 및 이의 사용 방법
KR20070057818A (ko) Ｒａｇｅ 융합 단백질 및 이의 사용 방법
TW201141507A (en) RAGE fusion protein compositions and methods of use
HK1129393A (en) Rage fusion proteins and methods of use
HK1104933A (zh) Rage融合蛋白及使用方法
NL2001558C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001557C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001553C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001551C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001554C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001552C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001556C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001555C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
HK1133042A (en) Rage fusion proteins, formulations, and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid